Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.
Brunt et al.·Journal of Clinical PsychopharmacologyImpact 1.6
Klarer NutzenGRADENiedrig65 Zitate
Stichproben = 102 Pat.
Dauermehr als ein Jahr bei 76% der…
EndpunktTherapeutische Zufriedenheit
Verblindungn.a.
DesignQuerschnittsstudie (Fragebogen)
Cannabinoidvollspektrum
”Kernaussage
Die Mehrheit der Patienten berichtete hohe therapeutische Zufriedenheit, wobei sich bestimmte subjektive Effekte zwischen den Cannabissorten mit unterschiedlichem THC/CBD-Gehalt unterschieden.
Zusammenfassung
Querschnittsstudie (n=102) bei niederländischen Patienten mit pharmazeutisch-qualifiziertem Cannabis; chronischer Schmerz häufigste Indikation (53%; n=54); 86% berichteten (fast) immer therapeutische Zufriedenheit beim Konsum; subjektive Schmerzlinderung als Hauptergebnis; keine Kontrollgruppe, keine Effektgrößen-Berechnung.
P
PopulationErwachsene Patientinnen und Patienten mit medizinischer Cannabisverordnung (vorwiegend chronischer Schmerz und Multiple Sklerose), n=102, Durchschnittsalter 53 Jahre
I
InterventionPharmazeutisch hergestelltes Cannabis (verschiedene Sorten mit unterschiedlichem THC/CBD-Gehalt), inhalativ oder oral, naturalistisches Setting
O
Outcome86% der Patienten berichteten (fast) immer therapeutische Zufriedenheit; Dejection, Angst und Appetitanregung unterschieden sich signifikant zwischen den 3 Sorten
Vertrauen in die Evidenz
Sehr niedrigNiedrigModeratHoch
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Qualitätsprofil
Größe★★★★★
Verblindung—
EffektstärkeKlarer Nutzen
Zitate / Jahr★★★★★
Autoren
Brunt TM, van Genugten M, Höner-Snoeken K, van de Velde MJ, Niesink RJ.
In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special focus on their delta-9-tetrahydrocannabinol and cannabidiol content. In a cross-sectional and natural design, users of pharmaceutical-grade cannabis were investigated with questionnaires. Medical background of the patients was asked as well as experienced therapeutic effects and characteristics of cannabis use. Subjective effects were measured with psychometric scales and used to compare among the strains of cannabis used across this group of patients. One hundred two patients were included; their average age was 53 years and 76% used it for more than a year preceding this study. Chronic pain (53%; n = 54) was the most common medical indication for using cannabis followed by multiple sclerosis (23%; n = 23), and 86% (n = 88) of patients (almost) always experienced therapeutic satisfaction when using pharmaceutical cannabis. Dejection, anxiety, and appetite stimulation were found to differ among the 3 strains of cannabis. These results show that patients report therapeutic satisfaction with pharmaceutical cannabis, mainly pain alleviation. Some subjective effects were found to differ among the available strains of cannabis, which is discussed in relation to their different tetrahydrocannabinol/cannabidiol content. These results may aid in further research and critical appraisal for medicinally prescribed cannabis products.